An open-label, multi-center extended phase II P2101B study for delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand.
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2017
At a glance
- Drugs GP120-depleted HIV-1 vaccine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 23 Feb 2017 New trial record
- 30 Dec 2016 Primary end point (CD4+ T cell counts) met according to Immune Response BioPharma Media Release.
- 30 Dec 2016 Results published in the Immune Response BioPharma Media Release.